The biotechnology sector, as measured by the XBI ETF, surged in pre-market trading, driven by a wave of positive clinical trial results and regulatory updates from several companies. Vir Biotechnology saw its stock jump 15% after announcing positive Phase 3 data for its hepatitis D drug. [7] Separately, Immunovant and Tango Therapeutics also reported encouraging trial results for their respective treatments. [2] This string of positive developments has bolstered investor confidence in the sector, overshadowing some negative trial news and suggesting a risk-on sentiment for biotech.